Alnylam Pharmace. Stock
Alnylam Pharmace. Stock
We can see a decrease in the price for Alnylam Pharmace.. Compared to yesterday it has lost -€7.300 (-2.300%).
With 52 Buy predictions and not a single Sell prediction Alnylam Pharmace. is an absolute favorite of our community.
With a target price of 412 € there is a positive potential of 30.71% for Alnylam Pharmace. compared to the current price of 315.2 €.
Our community identified positive and negative aspects for Alnylam Pharmace. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Alnylam Pharmace. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Pros and Cons of Alnylam Pharmace. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alnylam Pharmace. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | -2.300% | -12.856% | -6.911% | 34.989% | -6.966% | 45.120% | 132.106% |
| Ironwood Pharmaceuticals | -0.510% | 12.717% | 27.451% | 9.551% | 46.617% | -63.201% | -58.065% |
| Novocure Ltd | 1.070% | -4.094% | 4.229% | -53.571% | 4.367% | -86.363% | -91.952% |
| Iovance Biotherapeutics Inc. | 1.140% | -13.523% | 8.638% | -64.348% | -13.997% | -65.176% | -95.234% |
Comments
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Bank of America Corporation from $530.00 to $529.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Needham & Company LLC from $520.00 to $529.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Truist Financial Corporation from $535.00 to $530.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat